A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects

Inclusion Criteria:

- Female or male subjects with T1DM for at least 1 year, diagnostic criteria as defined
by the American Diabetes Association

- Treated with insulin for T1DM for at least 1 year and with stable insulin treatment
(defined as no more than a 10-unit daily variation in total daily insulin dose) 30
days prior to screening

- Hemoglobin A1c <10%

Exclusion Criteria:

- Previously treated with dasiglucagon (previously referred to as ZP4207)

- Known or suspected allergy to trial product(s) or related products

- Females who are pregnant according to a positive pregnancy test, are actively
attempting to get pregnant, or are lactating.

- History of hypoglycemic events associated with seizures in the last year prior to
screening

- History of severe hypoglycemia in the last month prior to screening

- Active malignancy within the last 5 years

- Current bleeding disorder, including anti-coagulant treatment

- Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma
(i.e. insulin secreting pancreas tumor)

- Use of a daily systemic beta-blocker drug, indomethacin, warfarin or anticholinergic
drugs in the previous 28 days before Day 1 of this trial

- Clinically significant abnormal ECG at screening as judged by the investigator

- Donation of blood or plasma in the past month, or in excess of 500 mL within 12 weeks
prior to screening

- Surgery or trauma with significant blood loss within the last 2 months prior to
screening

- A positive result in the alcohol and/or urine drug screen at the screening visit.
Significant history of alcoholism or drug abuse as judged by the investigator or
consuming more than 24 g alcohol per day for men, or more than 12 g alcohol per day
for women